Keyphrases
Schizophrenia
100%
Placebo-controlled Study
100%
Sildenafil
100%
Intracellular Signaling
25%
Placebo
25%
Cyclic GMP
25%
Memory Consolidation
25%
Phosphodiesterase Type 5 Inhibitors
25%
Symptom Score
25%
Dementia
12%
Antipsychotics
12%
Cognitive Effects
12%
N-methyl-D-aspartate Receptor (NMDAR)
12%
Receptor-mediated
12%
Long-term Potentiation
12%
Dysregulated
12%
Hospitalization
12%
Long-term Memory
12%
Therapeutic Effect
12%
Nitric Oxide
12%
Cognitive Performance
12%
Schizophrenic Patients
12%
Neuronal Nitric Oxide Synthase (nNOS)
12%
Memory Deficits
12%
Psychiatric Symptoms
12%
Cognitive Symptoms
12%
N-methylation
12%
Treatment Conditions
12%
Aspartic Acid
12%
Mediated Memory
12%
PDE
12%
Single Oral Dose
12%
Repeated Dosing
12%
Cognitive Test Battery
12%
Performance Rating
12%
Stable Dose
12%
Neuroscience
Placebo
100%
Sildenafil
100%
Memory Consolidation
25%
Cyclic Guanosine Monophosphate
25%
Phosphodiesterase V
25%
N-Methyl-D-Aspartic Acid
12%
Long-Term Potentiation
12%
NMDA Receptor
12%
Long-Term Memory
12%
Nitric Oxide
12%
Neuronal Nitric Oxide Synthase
12%
Amnesia
12%
Dextro Aspartic Acid
12%
Receptor
12%
Antipsychotic
12%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo-Controlled Study
100%
Sildenafil
100%
Placebo
25%
Cyclic GMP
25%
Phosphodiesterase V Inhibitor
25%
Nitric Oxide
12%
Receptor
12%
Amnesia
12%
Therapeutic Effect
12%
N Methyl Dextro Aspartic Acid Receptor
12%
N Methyl Dextro Aspartic Acid
12%
Antipsychotic
12%
Dextro Aspartic Acid
12%
Neuronal Nitric Oxide Synthase
12%